Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
Collegium Pharmaceutical, Inc. reports developments for a diversified biopharmaceutical business focused on commercial medicines for serious medical conditions. Its recurring news centers on JORNAY PM for ADHD, a neuropsychiatry growth business, and a responsible pain management portfolio that includes BELBUCA, Xtampza ER, Nucynta products and Symproic.
Company updates also cover operating and financial results, investor presentations, real-world data from pain medications, branded ADHD awareness campaigns, capital deployment, credit facilities, material agreements, shareholder voting matters and governance disclosures.
Collegium Pharmaceutical (Nasdaq: COLL) announced a collaboration with entrepreneur and advocate Paris Hilton to share her personal ADHD journey and treatment experience on Oct 29, 2025.
The campaign aims to reduce stigma and encourage patients to talk with healthcare providers about treatment options. The release notes ADHD prevalence estimates of 15.5 million adults and 6.5 million children in the U.S., with ~70% of cases persisting into adulthood. Paris Hilton described being diagnosed as a young adult and choosing treatment with JORNAY PM (methylphenidate HCl) ER, a nighttime-dosed stimulant that starts on waking and lasts through the day.
Collegium Pharmaceutical (Nasdaq: COLL) announced it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. The company will host a live conference call and webcast at 8:00 a.m. ET following the release.
Conference call dial-in numbers are (877) 407-8037 (U.S.) and (201) 689-8037 (International) referencing the “Collegium Pharmaceutical Q3 2025 Earnings Call.” An audio webcast and a replay will be available from the Investors section of the company website at www.collegiumpharma.com, with the replay posted about two hours after the event.
Collegium Pharmaceutical (Nasdaq: COLL) will present real-world data posters on its ADHD product Jornay PM at two fall conferences during ADHD Awareness Month.
At AACAP in Chicago (October 20-25, 2025) a poster titled "Determining the Optimal Dose of Methylphenidate HCl (JORNAY PM) in Adolescents and Adults" is scheduled for Oct 22, 4–6 p.m. CDT at Hyatt Regency. At NEI Fall Congress in Colorado Springs (Nov 6-9, 2025) a poster titled "JORNAY PM in Practice: Real-World Evidence Exploration of Utilization and Patient Response" is scheduled for Nov 7, 4–5 p.m. MST at Broadmoor West.
Important safety note: JORNAY PM is a Schedule II controlled stimulant with abuse, dependence, and cardiovascular and psychiatric risks; see prescribing information for details.
Collegium (Nasdaq: COLL) will ring the Nasdaq opening bell on October 14, 2025 at 9:30 a.m. ET to celebrate its 10-year anniversary as a publicly traded company.
The company highlighted its expansion into neuropsychiatry via the acquisition of Jornay PM for ADHD, noting Jornay PM is currently the fastest growing stimulant medicine for ADHD. Collegium said its financial strength, business development track record, and commercial expertise position it to continue serving patients and pursuing growth. A live stream of the Nasdaq opening bell will be available at the Nasdaq bell-ringing page.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its participation in three upcoming investor conferences in September 2025. The company will attend the 2025 Wells Fargo Healthcare Conference on September 4 in Boston, participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on September 8 at 2:35 p.m. ET in New York, and present at the H.C. Wainwright Global Investment Conference on September 9 at 10:30 a.m. ET in New York.
Live webcasts of the fireside chats will be accessible through Collegium's investor relations website, with replays available for 90 days after the presentations.
Collegium Pharmaceutical (Nasdaq: COLL) will present nine posters featuring real-world data from its pain management portfolio at PAINWeek 2025 in Las Vegas from September 2-5, 2025. The presentations will focus on data from their key products BELBUCA® and XTAMPZA® ER.
The research includes studies on treatment characteristics, safety profiles, economic burden, and clinical outcomes for chronic low back pain patients. Chief Medical Officer Thomas Smith emphasized that these findings will provide healthcare professionals with valuable insights to support clinical decision-making. The poster session is scheduled for September 4, 2025, from 4:00 to 5:30 PM PT.
Collegium Pharmaceutical (Nasdaq: COLL) reported strong Q2 2025 financial results, achieving record quarterly revenue of $188.0 million, up 29% year-over-year. The company's ADHD medication Jornay PM generated record revenue of $32.6 million with 23% prescription growth, while the pain portfolio contributed $155.4 million, up 7% year-over-year.
The company raised its 2025 guidance, now expecting full-year revenue between $745-760 million and adjusted EBITDA of $440-455 million. Q2 highlights include adjusted EBITDA of $105.1 million and cash position of $222.2 million. The Board authorized a new $150 million share repurchase program through 2026, following completion of a $25 million accelerated share repurchase.
Collegium Pharmaceutical (Nasdaq: COLL) has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025, before market opening. The company will host a conference call and webcast at 8:00 a.m. ET following the release.
Investors can access the conference call via (877) 407-8037 (U.S.) or (201) 689-8037 (International). An audio webcast will be available on the company's website investor section and will remain accessible for replay approximately two hours after the event.
Collegium Pharmaceutical (Nasdaq: COLL) has announced a new $150 million share repurchase program effective through December 31, 2026. This program replaces their previous $150 million authorization from January 2024, which expired with $65 million unused.
The company has demonstrated strong commitment to shareholder value, having returned $222 million to shareholders through repurchase programs since 2021. This includes a $25 million accelerated share repurchase initiated in May 2025. As of March 31, 2025, Collegium had approximately 32.1 million shares outstanding.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its participation in two upcoming investor conferences:
1. The Mizuho Neuro & Ophthalmology Summit 2025, where management will participate in a panel presentation on Wednesday, May 21, 2025, at 11:25 a.m. ET
2. The Jefferies Global Healthcare Conference, featuring a presentation on Thursday, June 5, 2025, at 1:25 p.m. ET. This presentation will be webcast live and accessible through the company's investor relations website, with a replay available for 90 days following the event.